Banoxantrone

N/A

Report date: 2022/11/25 17:25:08
NME

Base Information

Drug NameBanoxantrone
Drug Alias Namebanoxantrone巴诺蒽醌banoxantronumbanoxantronaAQ-4-N +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsSolid tumoursGlioblastomaLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBtg Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovacea Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursGlioblastomaLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank